Serum PCSK9 Correlates with PTX3 and Apolipoproteins B, A1, and C3 Concentrations in Patients with Type 2 Diabetes

Table 3

Pearson’s and Spearman’s^& correlation coefficients between PCSK9 and chosen variables in patients with type 2 diabetes in the studied group and according to statin treatment and presence of NAFLD.

Parameter	Total	Statin therapy			Nonalcoholic fatty liver disease
		Yes ()	No ()	Present ()	Absent ()
Age (yrs)	-0.21	-0.15	-0.17	-0.24	-0.29
Diabetes duration (yrs)	-0.11^&	0.01	-0.15^&	-0.16^&	-0.11^&
HbA1c (%)	-0.21	-0.02	-0.45	-0.23	-0.23
Waist circumference (cm)	0.10	-0.04	0.15	-0.01	0.32
WHR	-0.10	-0.22	0.09	-0.06	-0.11
BMI (kg/m^2)	0.21	0.06	0.22	0.12	0.39
SBP (mmHg)	0.04	0.01	0.13	0.02	-0.03
DBP (mmHg)	0.13	-0.01	0.23	0.21	0.01
TC (mmol/l)	0.59	0.51	0.64	0.57	0.60
TG (mmol/l)	0.35^&	0.26^&	0.43^&	0.39^&	0.41^&
HDL-C (mmol/l)	0.04	0.24	-0.22	-0.04	0.01
LDL-C (mmol/l)	0.50	0.45	0.56	0.46	0.51
Glucose (mmol/l)	0.07^&	0.26^&	-0.24	0.03	0.08^&
Creatinine (μmol/l)	-0.10^&	-0.32^&	0.22	-0.08^&	-0.16
Uric acid (μmol/l)	0.11	0.07	0.11	0.14	0.13
Bilirubin (μg/dl)	-0.12	-0.10	-0.13	-0.02	-0.23
CK-18 (U/l)	0.06^&	0.05^&	0.10^&	0.09^&	0.09^&
PTX3 (ng/ml)	0.47^&	0.42^&	0.52^&	0.41	0.48^&
apo B48 (ng/ml)	0.25^&	0.24^&	0.13^&	0.23^&	0.26^&
apo B100 (mg/dl)	0.43	0.39	0.44	0.49	0.34
apo A1 (mg/dl)	0.43	0.53	0.23	0.46	0.38
apo C3 (μg/dl)	0.29^&	0.20	0.24^&	0.44^&	0.06
sLDLr (ng/ml)	-0.80	-0.77	-0.80	-0.84	-0.75
FLI	0.26^&	0.07^&	0.36^&	0.28^&	0.38^&
AST (U/l)	-0.05^&	-0.14^&	0.11^&	-0.01^&	-0.07^&
ALT (U/l)	-0.03^&	-0.14^&	0.08^&	-0.03^&	0.01^&
GGTP (U/l)	-0.01^&	-0.09^&	0.08^&	-0.08^&	-0.05^&

, , and ; ^&Spearman correlation coefficient.